ALTATHERA Pharmaceuticals
AltaThera Pharmaceuticals is a Chicago-based hospital specialty pharmaceutical company that develops and commercializes Sotalol IV, an FDA-approved intravenous antiarrhythmic developed via pharmacometric PK/PD modeling. It serves U.S. electrophysiology specialists, pediatric cardiologists, and hospital systems treating adult and pediatric cardiac arrhythmias.
- Company typePrivate
- Founded2009
- HeadquartersChicago, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ALTATHERA Pharmaceuticals does
AltaThera Pharmaceuticals is a Chicago-based, privately held hospital specialty pharmaceutical company founded in 2009 that develops and commercializes intravenous cardiovascular therapies for cardiac arrhythmias. Its sole commercial product, Sotalol IV (sotalol hydrochloride injection, 10 mL vial at 15 mg/mL), is an FDA-approved intravenous antiarrhythmic indicated for adult and pediatric patients with life-threatening ventricular arrhythmias and atrial fibrillation/atrial flutter. Sotalol IV was one of the first drugs approved (March 2020) under the FDA's Model-Informed Drug Development (MIDD) Paired Meeting Pilot Program, in which the company used proprietary pharmacometric PK/PD modeling — rather than traditional clinical trials — to support regulatory submissions. The technology platform spans dosing optimization, pediatric extrapolation, QT-interval safety prediction, and pipeline development, and is applied across the full drug lifecycle.
The company's business model is the direct commercialization of a single prescription pharmaceutical product to hospital systems in the United States. AltaThera employs a field sales organization led by a VP of Sales, engages GPOs and IDNs for formulary inclusion, and operates an HCP ordering portal at sotaloliv.com, supported by a customer service line, a medical information hotline, and a market access team handling coding, billing, and reimbursement inquiries. Customers are hospital electrophysiology specialists, pediatric cardiology programs, and hospital pharmacy/procurement teams. Pricing is not publicly disclosed; economics flow through negotiated hospital and GPO contracts. The company has a senior leadership team spanning commercial pharma, pediatric and adult electrophysiology, and corporate finance, and is actively pursuing label and pipeline expansion in pediatric and congenital heart disease indications.
ALTATHERA Pharmaceuticals firmographics
Firmographics- Name
- ALTATHERA Pharmaceuticals
- Legal name
- AltaThera Pharmaceuticals, LLC
- Website
- https://altathera.com
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AltaThera Pharmaceuticals is a Chicago-based hospital specialty pharmaceutical company that develops and commercializes Sotalol IV, an FDA-approved intravenous antiarrhythmic developed via pharmacometric PK/PD modeling. It serves U.S. electrophysiology specialists, pediatric cardiologists, and hospital systems treating adult and pediatric cardiac arrhythmias.
- Ownership category
- akta.pro rank
ALTATHERA Pharmaceuticals industry classification
Industry- Product category
- Antiarrhythmic Hospital Pharmaceuticals
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Clinical Pharmacology & Pharmacometrics (Modeling & Simulation) (HLAIALAG)
Keywords
Where ALTATHERA Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ALTATHERA Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Sotalol IV Product Sales: AltaThera commercializes Sotalol IV (sotalol hydrochloride injection) as a hospital-use pharmaceutical product. Revenue is generated through product sales to hospitals and healthcare systems. US healthcare professionals can order via sotaloliv.com. The company also earns from product training and workflow integration support services to hospital accounts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Sotalol IV (sotalol hydrochloride injection, 10 mL vial, 15 mg/mL) — prescription pharmaceutical product with no public list price |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
ALTATHERA Pharmaceuticals product offering
Product offeringCore offering
AltaThera Pharmaceuticals develops and commercializes Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter in adult and pediatric patients. The product is developed through a proprietary Model-Informed Drug Development (MIDD) platform using pharmacometric PK/PD modeling, enabling rapid therapeutic assessment (1-hour IV loading) and shorter hospital stays (outpatient discharge in under 24 hours for appropriate patients).
Product overview
AltaThera Pharmaceuticals operates as a single-product company focused on Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic therapy. The company develops and commercializes hospital-use intravenous therapies for cardiovascular treatment. Sotalol IV is the core and only commercial product, designed for adult and pediatric patients with cardiac arrhythmias including atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias. The product enables rapid intravenous drug initiation, allowing faster therapeutic assessment and shorter hospital stays compared to traditional oral sotalol loading protocols.
Differentiator
Problem solved
Functional benefit
Brands
- Sotalol IV: Sotalol IV (sotalol hydrochloride injection) is an FDA-approved intravenous antiarrhythmic indicated for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation/flutter patients, for both adult and pediatric populations.
Products and services
- Sotalol IV (sotalol hydrochloride injection) FDA-approved intravenous antiarrhythmic (10 mL vial, 15 mg/mL) indicated for adult and pediatric patients for the treatment of life-threatening ventricular arrhythmias (including sustained ventricular tachycardia) and for the maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter. Enables rapid therapeutic assessment with maximum serum concentration reached in 1 hour and potential outpatient discharge in under 24 hours for adult patients with adequate renal function. Sold to hospitals and healthcare systems via direct sales and the sotaloliv.com HCP portal.
Quantifiable outcome
- Mean length of stay reduced to 0.8 days with Sotalol IV vs. 3.6 days for oral sotalol (PEAKS Registry, 151 patients)
- +3 more outcomes
Companies that use ALTATHERA Pharmaceuticals
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
ALTATHERA Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ALTATHERA Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- U.S. Food and Drug Administration (FDA)coreAltaThera was among the first pharmaceutical companies to participate in the FDA's MIDD (Model-Informed Drug Development) Paired Meeting Pilot Program. The FDA collaborated with AltaThera to review MIDD modeling data as the basis for Sotalol IV's 2020 approval — one of the first drugs approved under this regulatory pathway, using modeling rather than traditional clinical trials.
- Rush University Medical CenterminorAltaThera partnered with Rush University Medical Center to support arrhythmia research internationally. Through a charitable donation of IV Sotalol (sotalol hydrochloride injection 15mg/mL), AltaThera supported research on prophylaxis for post-operative dysrhythmias conducted at Hanoi Heart Hospital in Hanoi, Vietnam over 2019-2020.
- University of Pennsylvania (Veterinary Program)minorAltaThera donated vials of IV sotalol to the Veterinary Program at the University of Pennsylvania to support research into heart arrhythmias in dogs, particularly arrhythmogenic right ventricular cardiomyopathy (ARVC) in Boxers. Professor Anna Gelzer conducted electrophysiologic studies to test IV sotalol's ability to suppress arrhythmia inducibility.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
ALTATHERA Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Milestone Pharmaceuticals: Specialty cardiology pharmaceutical company developing acute cardiovascular therapies (Etripamil nasal spray for PSVT). Comparable in target market (hospital/EP specialists) and business model (specialty pharma focused on acute arrhythmia management).
- InCarda Therapeutics: Clinical-stage company developing an inhaled antiarrhythmic for atrial fibrillation. Comparable as a direct competitive antiarrhythmic development focused on acute arrhythmia management in cardiology.
Broad incumbents
- ANI Pharmaceuticals: Specialty pharmaceutical company with a focus on injectable and hospital-based therapeutics, including cardiovascular products. Comparable in hospital-channel distribution and specialty injectable orientation, though broader in therapeutic areas.
- Eagle Pharmaceuticals: Specialty pharmaceutical company focused on injectable and hospital-administered products, including cardiovascular injectables. Comparable in targeting hospital channels with differentiated injectable formulations.
- Amphastar Pharmaceuticals: Specialty injectable pharmaceutical company with a portfolio including cardiovascular and critical care injectables. Comparable in hospital-channel injectable focus and pursuit of differentiated formulations of off-patent molecules.
- Hikma Pharmaceuticals: Global specialty pharmaceutical company with a sizable injectable portfolio including cardiovascular hospital products. Comparable in hospital injectable channel and emphasis on reformulated/generic specialty injectables.
- Pfizer: Largest pharmaceutical company with established IV antiarrhythmic and cardiovascular hospital products (e.g., various IV cardiovascular therapeutics). Comparable via overlapping cardiovascular hospital channel and ownership of competing/similar assets.
- Viatris: Global pharmaceutical company with extensive generic injectable portfolio including cardiovascular products. Comparable in producing generic injectable formulations of off-patent molecules for hospital use.
- Teva Pharmaceuticals: Global pharmaceutical company with a large generic injectable portfolio including cardiovascular products. Comparable in distributing generic injectable formulations used in hospital settings.
Others
- Lexicon Pharmaceuticals: Cardiology/metabolic specialty pharmaceutical company. Comparable as a small-cap specialty pharma with cardiovascular focus, though addressing different therapeutic indications (e.g., heart failure).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
ALTATHERA Pharmaceuticals social profiles
Digital presenceALTATHERA Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
ALTATHERA Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
ALTATHERA Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ALTATHERA Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ALTATHERA Pharmaceuticals
What does ALTATHERA Pharmaceuticals do?
AltaThera Pharmaceuticals develops and commercializes Sotalol IV (sotalol hydrochloride injection), an FDA-approved intravenous antiarrhythmic for the treatment of life-threatening ventricular arrhythmias and maintenance of normal sinus rhythm in atrial fibrillation and atrial flutter in adult and pediatric patients. The product is developed through a proprietary Model-Informed Drug Development (MIDD) platform using pharmacometric PK/PD modeling, enabling rapid therapeutic assessment (1-hour IV loading) and shorter hospital stays (outpatient discharge in under 24 hours for appropriate patients).
Is ALTATHERA Pharmaceuticals a public or private company?
ALTATHERA Pharmaceuticals is a private company. It is classified as unknown and is currently operating.
When was ALTATHERA Pharmaceuticals founded?
ALTATHERA Pharmaceuticals was founded in 2009. It employs 11 to 50 people.
Where is ALTATHERA Pharmaceuticals based?
ALTATHERA Pharmaceuticals is headquartered in Chicago, United States, in the North America region.
How does ALTATHERA Pharmaceuticals make money?
One revenue line is on record: sotalol IV Product Sales.
Who are ALTATHERA Pharmaceuticals's main competitors?
Direct peers on record are Milestone Pharmaceuticals and InCarda Therapeutics. Broad incumbents are ANI Pharmaceuticals, Eagle Pharmaceuticals, Amphastar Pharmaceuticals, Hikma Pharmaceuticals, Pfizer, Viatris and Teva Pharmaceuticals. Lexicon Pharmaceuticals is listed as an others.
Does ALTATHERA Pharmaceuticals have an API?
No public API is recorded for ALTATHERA Pharmaceuticals.
What industry is ALTATHERA Pharmaceuticals in?
ALTATHERA Pharmaceuticals's product category is Antiarrhythmic Hospital Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIALAG, Clinical Pharmacology & Pharmacometrics (Modeling & Simulation). Its SIC code is 2834.